Pure Bioscience (PURE) Releases Earnings Results

Pure Bioscience (OTCMKTS:PURE) released its earnings results on Thursday. The company reported ($0.04) earnings per share for the quarter, Bloomberg Earnings reports. The business had revenue of $0.59 million during the quarter. Pure Bioscience had a negative return on equity of 264.14% and a negative net margin of 419.50%.

Shares of OTCMKTS:PURE traded up $0.02 during midday trading on Friday, reaching $0.50. The company’s stock had a trading volume of 2,482 shares, compared to its average volume of 22,079. The company has a market capitalization of $36.51 million, a PE ratio of -4.55 and a beta of -1.21. Pure Bioscience has a 12-month low of $0.38 and a 12-month high of $1.02.

COPYRIGHT VIOLATION WARNING: “Pure Bioscience (PURE) Releases Earnings Results” was first posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://dakotafinancialnews.com/2018/12/14/pure-bioscience-pure-releases-earnings-results.html.

About Pure Bioscience

PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. It manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection and formulates with other compounds.

See Also: Insider Trading – What You Need to Know

Earnings History for Pure Bioscience (OTCMKTS:PURE)

Receive News & Ratings for Pure Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pure Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply